ISTA Pharmaceuticals Reports Third Quarter 2009 Financi...(4 58517 65203 ...)

Date:11/3/2009

4 58,517 65,203 ------- ------- ------- ------- Income (loss) from operations 5,249 (5,097) (800) (25,007) Other (expense) income: Interest expense (2,364) (4,073) (5,647) (7,686) Gain (loss) on derivative valuation 319 (422) 1,158 (380) Loss on warrant valuation (3,396) - (50,703) - Other, net (725) 24 (1,183) 293 ------- ------- ------- ------- Total other expense, net (6,166) (4,471) (56,375) (7,773) ------- ------- ------- ------- Net loss $(917) $(9,568) $(57,175) $(32,780) ======= ======= ======= ======= Net loss per common share, basic and diluted $(0.03) $(0.29) $(1.72) $(0.99) ======= ======= ======= ======= Shares used in computing net loss per common share, basic and diluted 33,251 33,037 33,210 33,018

                             ISTA Pharmaceuticals, Inc.
                     Summary of Consolidated Balance Sheet Data
                                  (in thousands)
                                    (unaudited)

                                       September 30, 2009   December 31, 2008
                                                                 Adjusted

    Cash and cash equivalents                $55,037              $48,316
    Short-term investments                         -                4,700
    Working capital                           26,644               31,500
    Total assets                              84,970               82,660
    Total stockholders' deficit              (78,410)             (17,19
'/>"/>
SOURCE  ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs